Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis

This was a phase 3 randomized controlled trial involving 567 adult subjects with moderate to severe chronic plaque psoriasis. The study compared the efficacy and safety of bimekizumab against both placebo and the active comparator ustekinumab. The primary outcomes were the percentage of participants achieving a Psoriasis Area and Severity Index 90 (PASI90) response and an Investigator's Global Assessment (IGA) response of clear or almost clear at week 16. The trial had a follow-up period of 13.1 months.

No specific efficacy results, including absolute numbers, effect sizes, or statistical significance for the primary or any secondary outcomes, were reported in the provided data. Similarly, detailed safety data on adverse events, serious adverse events, discontinuations, and tolerability were not available. The funding source was UCB Biopharma SRL, the lead sponsor.

Key limitations include the absence of reported results, which prevents any assessment of the intervention's comparative efficacy or safety profile. The practice relevance cannot be determined without the complete trial findings. Clinicians should await the full, peer-reviewed publication of this trial's results to understand the magnitude of benefit, safety signals, and how bimekizumab may fit into the treatment landscape for plaque psoriasis.

When you're living with the painful, itchy, and visible patches of moderate to severe plaque psoriasis, finding a treatment that works is everything. A new drug called bimekizumab has entered the scene, and researchers wanted to see if it could be a better option. In a major late-stage trial involving 567 adults, they directly compared bimekizumab to a placebo and to ustekinumab, a drug many patients already use.

The goal was to see if bimekizumab could help more people achieve very clear skin. The study measured two key things: the percentage of people who saw a 90% improvement in their psoriasis area and severity, and the percentage whose skin was rated as 'clear' or 'almost clear' by a doctor. However, the specific results—how many people actually hit these targets, and how bimekizumab stacked up against the other treatments—have not been released.

We also don't know about the drug's safety from this announcement. Every medication can have side effects, but the details on what, if any, adverse events occurred during the 13-month study period are not available. The trial was funded by the company that makes bimekizumab, which is standard but is always a factor to consider. For now, the core question of whether this new drug is more effective or safer remains unanswered until the full data is shared.